LivaNova Q2 Earnings Call Highlights

3 weeks ago 12

MarketBeat

Wed, August 5, 2026 astatine 12:04 PM CDT 7 min read

Key Points

Interested successful LivaNova PLC? Here are 5 stocks we similar better.
Record Q2 performance: Revenue roseate 9.8% twelvemonth implicit twelvemonth connected a constant-currency ground to $391 million, portion adjusted EPS accrued to $1.26 from $1.05, supported by double-digit maturation successful Cardiopulmonary and Epilepsy.
2026 outlook raised: LivaNova accrued its full-year revenue-growth guidance to 8%–9% and adjusted EPS guidance to $4.30–$4.40, citing stronger Cardiopulmonary demand, pricing and reimbursement momentum successful Epilepsy, and improved execution.
Investment weighs connected currency flow: The institution raised capital-spending guidance to $135 cardinal and chopped adjusted free-cash-flow guidance to $140 million–$160 cardinal arsenic it invests successful manufacturing capacity, innovation and IT infrastructure; a caller oxygenator enactment is expected to materially summation output successful 2027.

LivaNova (NASDAQ:LIVN) reported grounds quarterly gross and adjusted net per stock for the 2nd 4th of 2026, citing double-digit reported maturation crossed its Cardiopulmonary and Epilepsy businesses. The institution raised its full-year gross and adjusted EPS outlook portion reducing its adjusted free-cash-flow forecast to relationship for accrued concern successful manufacturing capacity, innovation and IT infrastructure.

Second-quarter gross totaled $391 million, up 9.8% connected a constant-currency ground from a twelvemonth earlier. Foreign speech provided an astir $3 million, oregon 1%, year-over-year benefit. Adjusted diluted EPS roseate to $1.26 from $1.05 successful the 2nd 4th of 2025, aided by higher gross and a one-time tariff refund.

→ SpaceX's First Earnings Report Could Decide Whether Shorts oregon Bulls Have Control

"We delivered a beardown 4th of double-digit reported gross maturation with spot crossed each regions, driven by robust show successful our Cardiopulmonary and Epilepsy businesses," CEO Vladimir Makatsaria said.

Cardiopulmonary Growth and Oxygenator Supply Plans

Cardiopulmonary gross was $222 million, an summation of 10% from the prior-year quarter, led by maturation successful Europe. Heart-lung instrumentality gross grew successful the mid-teens, driven by accrued placements of the company's Essenz strategy and continued terms premiums, according to Makatsaria.

→ 3 Drone Stocks That Should Soar After the Summer Slump

Cardiopulmonary consumables revenue, excluding heart-lung instrumentality consumables, accrued successful the precocious azygous digits. Oxygenators and perfusion tubing kits each posted low-double-digit growth, partially offset by little maturation successful autotransfusion systems and cannula products.

Read Entire Article